Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.

Background: In the Phase‐III clinical trial, CheckMate 141, nivolumab significantly improved survival versus standard of care in patients with platinum‐refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods: This pooled analysis investigated the real‐world effectiveness of nivolumab, following prior platinum‐based therapy, in patients with R/M SCCHN from the United States (US) Flatiron Health database and German HANNA prospective observational study. Results: Overall, 782 patients (56% US; 44% Germany) were included. Median overall survival (OS) was 8.71 months, and progression‐free survival was 4.11 months. Eastern Cooperative Oncology Group Performance Status 0 or 1, platinum sensitivity, and older age were associated with longer OS, in which number of prior lines of therapy had no significant effect. Conclusion: These findings demonstrate survival benefits of nivolumab in patients with R/M SCCHN in the real‐world setting. The observed real‐world effectiveness of nivolumab aligns with the efficacy of nivolumab in CheckMate 141. [ABSTRACT FROM AUTHOR]